Proteomic Analyses of Fibroblast- and Serum-Derived Exosomes Identify QSOX1 as a Marker for Non-invasive Detection of Colorectal Cancer.
cancer-associated fibroblasts
colorectal cancer
exosomes
extracellular vesicles
liquid biopsy
tumour microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Mar 2021
17 Mar 2021
Historique:
received:
25
01
2021
revised:
12
03
2021
accepted:
13
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
The treatment of colorectal cancer (CRC) has improved during the last decades, but methods for crucial early diagnosis are yet to be developed. The influence of the tumour microenvironment on liquid biopsies for early cancer diagnostics are gaining growing interest, especially with emphasis on exosomes (EXO), a subgroup of extracellular vesicles (EVs). In this study, we established paired cancer-associated (CAFs) and normal fibroblasts (NF) from 13 CRC patients and investigated activation status-related protein abundance in derived EXOs. Immunohistochemical staining of matched patient tissue was performed and an independent test cohort of CRC patient plasma-derived EXOs was assessed by ELISA. A total of 11 differentially abundant EV proteins were identified between NFs and CAFs. In plasma EXOs, the CAF-EXO enriched protein EDIL3 was elevated, while the NF-EXO enriched protein QSOX1 was diminished compared to whole plasma. Both markers were significantly reduced in patient-matched CRC tissue compared to healthy colon tissue. In an independent test cohort, a significantly reduced protein abundance of QSOX1 was observed in plasma EXOs from CRC patients compared to controls and diagnostic ROC curve analysis revealed an AUC of 0.904. In conclusion, EXO-associated QSOX1 is a promising novel marker for early diagnosis and non-invasive risk stratification in CRC.
Identifiants
pubmed: 33802764
pii: cancers13061351
doi: 10.3390/cancers13061351
pmc: PMC8002505
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Krebshilfe
ID : KA 3511/3-1
Organisme : Deutschen Konsortium für Translationale Krebsforschung
ID : JF DKTK Surgery
Organisme : Roland Ernst Stiftung
ID : 5/15
Références
Trends Pharmacol Sci. 2019 Mar;40(3):172-186
pubmed: 30736982
J Neuroimmune Pharmacol. 2020 Sep;15(3):501-519
pubmed: 31065972
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1158-66
pubmed: 27197301
Cell Growth Differ. 1993 Jun;4(6):483-93
pubmed: 8396966
J Biomed Sci. 2009;16:33
pubmed: 19292890
Clin Cancer Res. 2013 Nov 1;19(21):5914-26
pubmed: 24052018
Int J Biol Sci. 2019 Aug 22;15(11):2320-2329
pubmed: 31595150
Cancers (Basel). 2020 May 16;12(5):
pubmed: 32429403
FEBS Lett. 2010 Apr 16;584(8):1521-5
pubmed: 20211621
Proteomics Clin Appl. 2020 Jan;14(1):e1900052
pubmed: 31502404
Nucleic Acids Res. 2019 Jan 8;47(D1):D516-D519
pubmed: 30395310
Oncogene. 2012 Mar 1;31(9):1130-42
pubmed: 21804603
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Clin Chim Acta. 2018 Aug;483:151-155
pubmed: 29715435
Nat Med. 2012 Sep;18(9):1359-68
pubmed: 22863786
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
J Cell Biol. 1998 Mar 23;140(6):1383-93
pubmed: 9508771
Cancer Res. 2007 May 1;67(9):4138-48
pubmed: 17483324
Gastroenterology. 2005 Jan;128(1):51-62
pubmed: 15633123
Cell. 2011 Jul 8;146(1):148-63
pubmed: 21729786
Oncol Lett. 2017 May;13(5):3608-3616
pubmed: 28521461
Mol Diagn Ther. 2017 Apr;21(2):225-232
pubmed: 28155091
Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7160-5
pubmed: 21474781
Adv Drug Deliv Rev. 2018 Feb 1;125:102-121
pubmed: 29355669
PLoS One. 2015 Oct 13;10(10):e0139918
pubmed: 26461935
Lancet. 2005 Jan 8-14;365(9454):153-65
pubmed: 15639298
Br J Cancer. 2014 Jan 21;110(2):441-9
pubmed: 24292449
Cell Rep. 2017 May 9;19(6):1268-1280
pubmed: 28494874
Nat Med. 2008 May;14(5):518-27
pubmed: 18438415
Breast Cancer Res. 2012 Oct 25;14(5):R136
pubmed: 23098186
Ann Transl Med. 2017 Feb;5(3):46
pubmed: 28251125
Cancers (Basel). 2019 Jun 25;11(6):
pubmed: 31242686
PLoS Biol. 2012;10(12):e1001450
pubmed: 23271954
Anticancer Res. 2002 Nov-Dec;22(6C):3941-8
pubmed: 12553016
Biochem Biophys Res Commun. 2020 Mar 12;523(3):588-594
pubmed: 31941606
Medicine (Baltimore). 2015 Apr;94(13):e663
pubmed: 25837757
J Exp Med. 2013 Dec 16;210(13):2851-72
pubmed: 24323355
Br J Cancer. 2017 Aug 8;117(4):563-571
pubmed: 28664914
Mol Cancer. 2019 May 7;18(1):91
pubmed: 31064356
Clin Transl Oncol. 2020 Oct;22(10):1730-1740
pubmed: 32052380
Oncol Lett. 2019 Sep;18(3):2448-2454
pubmed: 31452735
Mol Oncol. 2013 Dec;7(6):1031-42
pubmed: 23998958
Histopathology. 2009 Jun;54(7):820-8
pubmed: 19635101
Nucleic Acids Res. 2019 Jan 8;47(D1):D506-D515
pubmed: 30395287
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Int J Cancer. 2018 Nov 1;143(9):2092-2104
pubmed: 29524224
Signal Transduct Target Ther. 2020 Mar 20;5(1):22
pubmed: 32296018
Science. 2008 Nov 14;322(5904):1101-4
pubmed: 19008446
J Proteomics. 2016 Jan 10;131:17-28
pubmed: 26463135
Cancer Biol Ther. 2005 Dec;4(12):1361-6
pubmed: 16258261
Cancer Manag Res. 2019 Jun 06;11:5271-5291
pubmed: 31239778
Int J Mol Sci. 2019 Nov 29;20(23):
pubmed: 31795332
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):137-44
pubmed: 15000154
Ann Oncol. 2019 Oct 1;30(10):1622-1629
pubmed: 31504112
Methods Mol Biol. 2018;1711:133-148
pubmed: 29344888
PLoS One. 2014 Feb 06;9(2):e87761
pubmed: 24516561
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):67-71
pubmed: 8118388
J Cancer Res Clin Oncol. 2016 Sep;142(9):1897-907
pubmed: 26987524
Mol Oncol. 2014 Oct;8(7):1290-305
pubmed: 24839936
Cancers (Basel). 2019 Jun 19;11(6):
pubmed: 31248203
Prostate. 2019 Oct;79(14):1589-1596
pubmed: 31376183
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Theriogenology. 2018 Jul 1;114:301-307
pubmed: 29677633
Front Cell Dev Biol. 2020 Jun 16;8:478
pubmed: 32612994
Biofactors. 2009 May-Jun;35(3):258-65
pubmed: 19422052
Nat Protoc. 2016 Dec;11(12):2301-2319
pubmed: 27809316
Cancer Lett. 2019 Feb 1;442:287-298
pubmed: 30439539
J Clin Invest. 2016 Nov 1;126(11):4140-4156
pubmed: 27701147
Am J Physiol Heart Circ Physiol. 2002 May;282(5):H1924-32
pubmed: 11959660
J Thorac Oncol. 2017 Jan;12(1):65-76
pubmed: 27613525
Pathol Res Pract. 2018 Jul;214(7):964-967
pubmed: 29804717
JCI Insight. 2019 Jul 25;5:
pubmed: 31343988
Cancer Res. 2005 Oct 1;65(19):8836-45
pubmed: 16204054
PLoS One. 2010 Nov 11;5(11):e13921
pubmed: 21085685
Annu Rev Biochem. 2019 Jun 20;88:487-514
pubmed: 31220978
Gastroenterology. 2010 May;138(5):1714-26
pubmed: 20100481
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Cancer Res. 2011 Dec 15;71(24):7490-501
pubmed: 22028325
Nat Protoc. 2006;1(6):2856-60
pubmed: 17406544
Int J Mol Sci. 2020 Feb 19;21(4):
pubmed: 32092975
J Thorac Oncol. 2015 Feb;10(2):286-301
pubmed: 25299231
RNA Biol. 2019 Oct;16(10):1339-1345
pubmed: 31251124
BMC Cancer. 2014 Sep 18;14:677
pubmed: 25234557
Proteomics. 2016 Apr;16(8):1280-90
pubmed: 26915739
Oncol Lett. 2019 Oct;18(4):4160-4166
pubmed: 31579419
Int J Mol Sci. 2018 Oct 17;19(10):
pubmed: 30336636
Clin Cancer Res. 2013 Nov 1;19(21):6006-19
pubmed: 24025712
Cancers (Basel). 2020 Apr 04;12(4):
pubmed: 32260433
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Radiother Oncol. 2010 Oct;97(1):149-61
pubmed: 20888056
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Biochem Cell Biol. 2019 Dec;97(6):731-739
pubmed: 31199884
Oncology. 2018;94(4):243-256
pubmed: 29393238
Neoplasia. 2004 Jan-Feb;6(1):1-6
pubmed: 15068665
BMC Cancer. 2019 Mar 29;19(1):284
pubmed: 30922247
Cancers (Basel). 2020 May 28;12(6):
pubmed: 32481658
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Int J Cancer. 2012 Mar 15;130(6):1264-72
pubmed: 21445967
Oncotarget. 2020 Jan 28;11(4):386-398
pubmed: 32064042
Breast Cancer Res. 2016 Aug 11;18(1):84
pubmed: 27515302
J Urol. 2014 Aug;192(2):583-92
pubmed: 24530986
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2019 Sep;35(9):828-831
pubmed: 31750826